Posaconazole for lobomycosis

Pasqualotto, Alessandro C.; Filho, Sérgio D. Jaskulski; Sena, Maria Gorete de; Santos, Auri Ferreira dos; Severo, Marilia M.S.

doi:10.1016/j.bjid.2021.101576

Cited by 5 publications

(7 citation statements)

References 1 publication

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lastly, a 57-year-old Brazilian man showing the disseminated form of lobomycosis was treated with posaconazole (400 mg/twice daily) for 30 months [ 72 ]. This patient had previously undergone treatment with itraconazole, dapsone, and clofazimine with no remarkable success.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Lobomycosis Epidemiology and Management: The Quest for a Cure for the Most Neglected of Neglected Tropical Diseases

Gonçalves

Rosa

Belone

et al. 2022

JoF

View full text Add to dashboard Cite

Lobomycosis is a chronic disease caused by Lacazia loboi, which is endemic to the Amazon rainforest, where it affects forest dwellers in Brazil. There is no disease control program and no official therapeutic protocol. This situation contributes to an unknown disease prevalence and unmet needs of people disabled by this disease who seek access to treatment. This review provides an update on the subject with an emphasis on therapeutic advances in humans. All relevant studies that addressed epidemiology, diagnosis, or therapeutics of lobomycosis were considered. Seventy-one articles published between 1931 and 2021 were included for a narrative literature review on the epidemiology and quest for a cure. An effective therapy for lobomycosis has been found following decades of research led by the State Dermatology Program of Acre in the Amazon rainforest, where the largest number of cases occur. This discovery opened new avenues for future studies. The main recommendations here, addressed to the Brazilian Ministry of Health, are for lobomycosis to become a reportable disease to ensure that disease prevalence is measured, and that it be prioritized such that affected individuals may access treatment free-of-charge.

show abstract

Section: Resultsmentioning

confidence: 99%

“…This patient had previously undergone treatment with itraconazole, dapsone, and clofazimine with no remarkable success. A regimen of posaconazole decreased skin lesions in size and healed some of them, with no side effects [ 72 ] ( Table 1 ). This further shows that posaconazole is a potential adjuvant drug for lobomycosis therapeutics.…”

Section: Resultsmentioning

confidence: 99%

Lobomycosis Epidemiology and Management: The Quest for a Cure for the Most Neglected of Neglected Tropical Diseases

Gonçalves

Rosa

Belone

et al. 2022

JoF

View full text Add to dashboard Cite

show abstract

“…Lobomycosis or Lacaziosis or Jorge Lobo's disease or Keloidal Blastomycosis, or Amazonic Blastomycosis, is a chronic granulomatous infection of the cutis and subcutis caused by the fungal species L. loboi (formerly Loboa loboi and Paracoccidioides loboi) that can infect humans and dolphins (Arenas et al, 2019;Arju et al, 2014;de Sousa et al, 2015;Francesconi et al, 2014;Grayson & Colonje, 2020;Hall et al, 2017;Pasqualotto et al, 2021;Queiroz-Telles et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

“…Treatment can be in the form of giving clofazimine or clofazimine together with itraconazole, (Hall et al, 2017) although until now, there is no antimycotic that is effective (Arenas et al, 2019). The Pasqualotto study, AC., 2021, reported that chronic renal failure patients who had undergone hemodialysis with extensive lobomycosis with extensive clinical manifestations of keloidal-like lesions showed a good response to the use of posaconazole, and it is hoped that long-term therapy can give better results (Pasqualotto et al, 2021).…”

Section: Discussionmentioning

confidence: 99%

“…Lobomycosis is a chronic granulomatous infection of the cutis and subcutis caused by the fungal species Lacazia loboi (Arju et al, 2014;de Sousa et al, 2015;Grayson & Colonje, 2020;Hall et al, 2017;Pasqualotto et al, 2021;Queiroz-Telles et al, 2017). This disease is endemic to tropical forest areas of Central and South America, particularly in the Amazon basin, (Grayson & Colonje, 2020) and cases are very rarely reported outside this area (Beltrame et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lobomycosis post long-term corticosteroid therapy: a case report

Saputra

Sriwidyani

Paskarani

et al. 2022

RSD

View full text Add to dashboard Cite

Introdução: A lobomicose é uma das infecções fúngicas mais raramente relatadas em todo o mundo. A maioria dos casos relatados de lobomicose é endêmica na América Central e do Sul, especialmente em torno da Amazônia. As áreas do corpo afetadas geralmente são as orelhas, extremidades inferiores, extremidades superiores, rosto, tórax e costas. Objetivo: apresentar a evolução da lobomicose após corticoterapia de longa duração. Metodologia: Estudo descritivo do tipo relato de caso, cujos dados foram obtidos no prontuário do paciente. Apresentação do caso: Este artigo relata uma mulher de 23 anos, que sofreu feridas que cobriam quase toda a superfície do corpo sem qualquer febre. Ao exame físico, foram encontradas múltiplas úlceras com maceração das bordas da ferida e múltiplas saliências avermelhadas nas regiões anterior e posterior do tronco. Não há aparecimento de quelóides. O paciente tinha história de pênfigo vulgar e pênfigo vegetante e estava em uso de corticoterapia por longo prazo. O exame microbiológico não revelou crescimento de fungos. O exame histopatológico do tecido com coloração de Hematoxilina-Eosina e Ácido Periódico de Schiff (PAS) confirmou o diagnóstico de lobomicose. Conclusão: Com base nos achados clínicos e laboratoriais, o paciente foi diagnosticado com Lobomicose.

show abstract

Clofazimine/dapsone/itraconazole

2021

Reactions Weekly

View full text Add to dashboard Cite

Posaconazole for lobomycosis

Cited by 5 publications

References 1 publication

Lobomycosis Epidemiology and Management: The Quest for a Cure for the Most Neglected of Neglected Tropical Diseases

Lobomycosis Epidemiology and Management: The Quest for a Cure for the Most Neglected of Neglected Tropical Diseases

Lobomycosis post long-term corticosteroid therapy: a case report

Clofazimine/dapsone/itraconazole

Contact Info

Product

Resources

About